Search the Newsreel

How Investors Are Reacting To Public Service Enterprise Group (PEG) Rising Revenue But Weaker Q2 Earnings

Nectar Lifesciences Publishes Q1 FY2026 Results in Press and Online

Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding

Alto Neuroscience (ANRO) saw a 13.5% stock increase after expanding its ALTO-207 Phase 3 trial for treatment-resistant depression and securing approximately $100 million in new funding. Despite ongoing net losses, the company aims to validate its data-driven approach, with short-term focus on the expanded …

Trading the Move, Not the Narrative: (INBX) Edition

This article provides an in-depth analysis of Inhibrx Biosciences Inc (INBX), highlighting strong sentiment across all time horizons and an exceptional 100.9:1 risk-reward setup. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide trading decisions.

ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise

Ck Life Sciences Int'l., (Holdings) - LSI - Stock Price & News

How Investors Are Reacting To Forte Biosciences (FBRX) Widening Losses But Slightly Improved Per-Share Results

Forte Biosciences reported increased net losses in Q2 and H1 2026 but saw a slight improvement in basic loss per share due to share count adjustments. The company's investment narrative is now heavily tied to its pending sale to argenx and the cash tender …

Oppenheimer Asset Management Inc. Invests $9.62 Million in MSCI Inc $MSCI

Oppenheimer Asset Management Inc. recently invested $9.62 million in MSCI Inc. by acquiring 17,171 shares during the second quarter. Institutional investors collectively own 89.97% of MSCI. Despite a modest miss on Q2 earnings and revenue, analysts generally maintain a "Buy" rating with a target …

Mill Capital Management LLC Invests $9.85 Million in Boston Scientific Corporation $BSX

Mill Capital Management LLC has invested $9.85 million in Boston Scientific Corporation, acquiring 230,815 shares. Institutional investors collectively own 89.07% of the company's stock, and despite a recent growth slowdown in key businesses, analysts maintain a "Moderate Buy" consensus rating with an average price …

CSTL (CSTL) insider and family trusts detail planned and recent stock sales

A recent SEC Form 144 filing indicates a planned sale of 25,792 shares of CSTL common stock, valued at $763,959.04, by an insider and related family trusts, to be executed around August 14, 2026, through Goldman Sachs & Co. LLC. The filing also details …

Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRA

Walleye Capital LLC has acquired a new stake of 347,898 shares in Tyra Biosciences, Inc. (NASDAQ:TYRA), valued at approximately $11.1 million, bringing institutional ownership in the company to 84.14%. Despite the stock opening at $25.29, well below its 52-week high, analysts maintain a "Moderate …

Walleye Capital LLC Buys Shares of 386,183 IDEAYA Biosciences, Inc. $IDYA

Walleye Capital LLC has acquired 386,183 shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the second quarter, a new stake valued at approximately $14.4 million. This purchase represents 0.44% of IDEAYA Biosciences. Despite a reported quarterly loss of $1.22 per share, institutional ownership of the …

Forte Biosciences, Inc. (NASDAQ:FBRX) Given Average Recommendation of "Hold" by Brokerages

Forte Biosciences, Inc. (NASDAQ:FBRX) has received an average "Hold" rating from seven brokerages, with an average 12-month price target of $72.50, below its current $76.83 stock price. Recent analyst coverage has generally been negative, including downgrades from Wall Street Zen, Weiss Ratings, Barclays, and …

Dockside LLC Takes Position in MSCI Inc $MSCI

Dockside LLC has acquired a new stake in MSCI Inc, purchasing 6,832 shares valued at approximately $3.83 million, making MSCI 0.9% of its portfolio. This comes as MSCI faces mixed sentiment, with positive news from its August index review expected to drive rebalancing and …

Absci Corporation (NASDAQ:ABSI) Receives Consensus Rating of "Moderate Buy" from Analysts

Absci Corporation (NASDAQ:ABSI) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $13.43. Despite missing quarterly earnings and revenue estimates, institutional investors hold over 52% of the stock. The company leverages machine learning and synthetic biology in …

Value Partners Investments Inc. Reduces Holdings in Thermo Fisher Scientific Inc. $TMO

California State Teachers Retirement System Has $1.12 Million Stock Holdings in Kodiak Sciences Inc. $KOD

Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Average Recommendation of "Moderate Buy" by Brokerages

Assembly Biosciences (NASDAQ:ASMB) has received an average "Moderate Buy" recommendation from brokerages, with five out of seven analysts rating the stock a buy. The average 12-month price target for ASMB is $44.00, significantly higher than its recent price of $32.95. The company also reported …

Security National Bank Boosts Stock Position in Thermo Fisher Scientific Inc. $TMO

Security National Bank increased its stake in Thermo Fisher Scientific Inc. (TMO) by 18.5% in the second quarter, bringing its total holdings to 14,095 shares valued at approximately $7.1 million. The article also notes that institutional investors own 89.23% of TMO, and analysts generally …

Gufic Biosciences Q1 Results: Net profit up 23% YoY to ₹80 crore

Everett Harris & Co. CA Acquires Shares of 80,341 Edwards Lifesciences Corporation $EW

Everett Harris & Co. CA has purchased 80,341 shares of Edwards Lifesciences Corporation (NYSE:EW) for approximately $7.27 million during the second quarter, marking a new stake in the company. This comes as other institutional investors have also adjusted their holdings in the medical research …

California State Teachers Retirement System Purchases 21,011 Shares of MBX Biosciences, Inc. $MBX

The California State Teachers Retirement System significantly increased its stake in MBX Biosciences by 1,197.9%, now holding 22,765 shares valued at $680,000. Other institutional investors also raised their positions in the company. Despite the company missing its Q2 earnings estimates, analysts maintain a "Moderate …

Dimensional Fund Advisors LP Invests $1.40 Million in MBX Biosciences, Inc. $MBX

Dimensional Fund Advisors LP has acquired a new stake worth $1.40 million in MBX Biosciences, Inc., representing 0.10% of the company. Other institutional investors have also increased their positions in MBX. Despite missing earnings estimates for the recent quarter, analysts generally maintain a "Moderate …

Cannon Advisors Inc. Acquires New Shares in Thermo Fisher Scientific Inc. $TMO

Cannon Advisors Inc. recently purchased 3,971 shares of Thermo Fisher Scientific Inc. (NYSE:TMO) valued at approximately $2.12 million, making it their 17th biggest position. This acquisition comes as other hedge funds have also adjusted their holdings in TMO, while company insiders have sold a …

Canoe Financial LP Buys 148,999 Shares of Thermo Fisher Scientific Inc. $TMO

Abundance Wealth Counselors Grows Stake in Gilead Sciences, Inc. $GILD

Abundance Wealth Counselors significantly increased its stake in Gilead Sciences, Inc. by 93.7% in the second quarter, now holding 22,139 shares valued at $2.8 million. This comes as Gilead reported strong Q2 revenue growth of 10.6% to $7.8 billion, driven by its HIV franchise …

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of "Moderate Buy" from Brokerages

IDEAYA Biosciences (NASDAQ:IDYA) has received an average rating of "Moderate Buy" from sixteen brokerages, with an average 12-month price target of $50.13, significantly above its current share price of $36.30. The company's recent quarterly results showed revenue exceeding expectations but missed on earnings per …

Handelsbanken Fonder AB Has $6.27 Million Position in Roivant Sciences Ltd. $ROIV

Handelsbanken Fonder AB significantly increased its stake in Roivant Sciences Ltd. during the second quarter, now holding 177,209 shares valued at $6.27 million. Institutional investors collectively own 64.76% of Roivant's stock, despite recent insider selling totaling approximately 2.06 million shares. Analysts maintain a "Moderate …

Science Applications International Corporation $SAIC Shares Acquired by Bank of America Corp DE

Bank of America Corp DE increased its stake in Science Applications International Corporation (SAIC) by 17.5% in the first quarter, acquiring an additional 56,720 shares, bringing its total to 380,538 shares valued at $36.1 million. The company's stock is primarily held by institutional investors, …

Key facts: MSTR fails MSCI tests; Norway GPFG BTC tied to MSTR

MicroStrategy (MSTR) failed four out of five MSCI non-operating company tests in May 2026, potentially leading to its reclassification as an asset-holding company and removal from MSCI indexes. Concurrently, Norway's Government Pension Fund Global (GPFG) holds 11,549 BTC and has significant indirect Bitcoin exposure …

Nectar Lifesciences to Relocate Corporate Office Within Chandigarh Industrial Hub

T. Rowe Price Associates (TWST) discloses 3.63M-share Twist Bioscience position

T. Rowe Price Associates has reported a beneficial ownership of 3,634,470 shares of Twist Bioscience Corp. (TWST), representing a 5.8% stake in the company's common stock. The firm holds sole voting power over 3,520,536 shares and sole dispositive power over all 3,634,470 shares, as …

Precision Trading with Wave Life Sciences Ltd. (WVE) Risk Zones

This article from Stock Traders Daily provides a detailed analysis of Wave Life Sciences Ltd. (WVE), highlighting weak sentiment across all horizons supporting a short bias. It outlines institutional trading strategies, including long, breakout, and short positions, with specific entry zones, targets, and stop …

Gilead Sciences (NASDAQ:GILD) Upgraded to "Buy" at Wall Street Zen

Wall Street Zen has upgraded Gilead Sciences (NASDAQ:GILD) from a "Hold" to a "Buy" rating. This upgrade aligns with a "Moderate Buy" consensus among analysts, with an average price target of $158.04. The company recently reported strong quarterly results, exceeding revenue expectations, despite some …

Wall Street Zen Downgrades Kodiak Sciences (NASDAQ:KOD) to Sell

Wall Street Zen downgraded Kodiak Sciences (NASDAQ:KOD) from "hold" to "sell" on Saturday, despite the broader analyst consensus being a "Moderate Buy." The company's shares opened near their 52-week high at $41.35, but Kodiak Sciences reported a larger-than-expected quarterly loss of $1.05 per share. …

IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen downgraded IDEAYA Biosciences (NASDAQ:IDYA) from "hold" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $50.12. The company's shares opened at $36.30, and it recently reported a quarterly loss of $1.22 per share, …